Long-Acting Injectable HIV Treatment Shows Promise In Clinical Trials
Associated Press: J&J, ViiV: 2 injections every month or 2 could control HIV
“Preliminary testing of two long-acting injectable drugs indicates it might be possible to keep HIV at bay indefinitely with injections every month or two. Johnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, on Tuesday announced results from the first 32 weeks of the planned 96-week study, which combines one drug from each company…” (Johnson, 11/3).
Reuters: Bi-monthly injection blocks HIV in study from J&J and GSK
“…Paul Stoffels, J&J’s head of pharmaceuticals, said the finding offered a potentially ‘transformational’ way to fight HIV, if the result is confirmed in larger final-stage trials. He believes the combination could be on the market by 2020…” (11/3).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.